We’re ScreenPoint Medical
-
Bringing AI to the fight against breast cancer
We’re ScreenPoint Medical
We are bringing AI to the fight against breast cancer with leading clinical evidence and the latest deep learning technology.
Improve patient outcomes

Deep learning from the start
See why users trust Transpara
In the decade since its founding, ScreenPoint and its flagship product Transpara have helped thousands of radiologists and supported care for millions of women with a relentless focus on improving workflow, increasing confidence and delivering clinically and operationally relevant results. That’s why users trust Transpara.






Our partners, your workflow
Improve patient outcomes
At ScreenPoint, we know that breast imaging – and particularly breast screening – cannot function without effective workflow. To support our customers, we have designed an offering that is flexible and environment agnostic. Transpara works on 2D and 3D acquisitions, and our detection algorithm works on gantries from every major manufacturer. Regardless of your workflow, we want to fit seamlessly into your toolkit, so we work hard to ensure a seamless integration regardless of acquisition and reading environments.

Research Grants & Funding
Our commitment to advancing breast cancer detection is supported by leading research grants. These funds allow us to drive innovation, enhance clinical outcomes, and collaborate with top research institutions.
The “Autonomous AI for Cancer Detection” project is supported by the European Fund for Regional Development and brings together ScreenPoint Medical, Radboud University Medical Center (Radboud UMC), and Thirona. Together, these partners are developing AI tools to support the early detection of breast and lung cancer, aiming to improve clinical outcomes and streamline diagnostic workflows.
Project runtime: Jan 2025 – End of 2027
Within aiEMBRACE, ScreenPoint partners up with Netherlands Cancer Institute (NKI-AVL, Amsterdam), Memorial Sloan Kettering (MSKCC, NY), and Radboudumc (RUMC, Nijmegen) starting in Q4 2023 and will, for the next four years, advance AI-based technology to support women at elevated risk in their breast cancer patient journey from screening and diagnostics to treatment and follow up.
- MRI breast cancer detection algorithms
- Risk algorithms for future breast cancer development (MG and MR)
- Cancer recurrence and prediction
- Treatment response monitoring and prediction
Project runtime: Nov 2023 – Nov 2026